Atlas Trials

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Clinical trial NCT06759636 · RECRUITING

Trial details

NCT number
NCT06759636
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
CTIT: Cancer Therapy Induced Thrombocytopenia
Start date
2025-02-24
Primary completion
2026-04-21
Enrollment
88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.